Table 7_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 2_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 3_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 4_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xls by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 1_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 6_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 5_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.docx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table4_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Image1_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.JPEG by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Table3_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Image2_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.JPEG by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Table1_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Image3_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.JPEG by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Table2_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Functional enrichment analysis. by Andrea Salinas (4963834)

“…Finally, the extract significantly decreased concanavalin A (ConA)-induced T cell proliferation. …”

Supplementary file 1_Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study.docx by Ji-Xin Tian (21710993)

“…The use of azole antifungals was a significant factor influencing VEN concentration (P < 0.05). …”

Mutation of 1G05 epitope glycan sites impacts avidity. by Zachary T. Berndsen (9230176)

Supplementary Material for: Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by figshare admin karger (2628495)

“…Methods For this subanalysis, efficacy outcomes included a CV composite (time to CV death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% estimated glomerular filtration rate [eGFR] decrease from baseline over ≥4 weeks or renal death) outcome. …”

Glia-targeted 5-HT_2A receptor expression in adults reopens experience-dependent synaptic glomeruli pruning. by Vanessa Kay Miller (19775496)

“…There is a significant decrease in the Or42a OSN innervation volume with glial-targeted <i>Gal80</i>^<i>ts</i><i>-5-HT</i>_<i>2A</i><i>R</i> OE at 28°C (<i>n</i> = 20/condition, <i>p</i> = 1.00 × 10⁻¹⁵). …”

Table 1_The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.docx by Yutong Wu (3130584)

“…Notably, we detected several potential safety signals not currently listed in the prescribing information: Malignant neoplasm progression, weight decreased, sepsis myocarditis, encephalitis and hypotension.…”